Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance of the surrogate clinical trial endpoint “reduction in proteinuria” has enabled early approval of therapeutic agents labeled for IgAN: Calliditas Therapeutics’ Tarpeyo (DR-budesonide), Travere Therapeutics’ Filspari (sparsentan), and Novartis’s Fabhalta (iptacopan) and Vanrafia (atrasentan). Because all approved targeted therapies are expensive, payers usually restrict their access to patients at high risk of disease progression. Several therapies are also in late-phase development for IgAN. This report examines the prescribing and reimbursement environment for key current and emerging IgAN agents in the United States according to surveyed nephrologists and MCO PDs / MDs. It explores how physicians and payers perceive current and emerging IgAN therapies and the reimbursement dynamics that will promote or restrict market access to the agents.
QUESTIONS ANSWERED
- How do MCO restrictions impact physicians’ prescribing of branded therapies / targeted agents for IgA nephropathy? What is the state of coverage of Tarpeyo, Filspari, and Fabhalta?
- How do market access dynamics influence surveyed nephrologists’ prescribing?
- How do MCOs cover branded therapies / targeted agents in their largest fully insured commercial plans, and which utilization management controls do they use?
- How receptive are nephrologists and payers to emerging drugs (e.g., Vera Therapeutics’ APRIL/BAFF inhibitor atacicept, Novartis’s endothelin receptor antagonist atrasentan)? What points of differentiation are / will be most compelling to nephrologists and payers of new therapies for IgAN?
PRODUCT DESCRIPTION
Leveraging Clarivate’s proprietary data sources and surveys with physicians and payers, Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of payer policy on physician prescribing behavior in the United States. Through detailed analyses of drug coverage, restriction policies, and contracting, as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies, this report enables you to:
- Identify and learn how to overcome roadblocks to market access to best position your brand.
- Identify key stakeholders and reimbursement drivers and assess the impact that reimbursement decisions have on treatment selection.
Primary research: Survey of 101 U.S. nephrologists and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).
Fingertip Formulary: Formulary coverage by commercial plans covering 164.3 million lives nationally.
Real-world data: U.S. pharmacy and medical claims data
Key drugs: Tarpeyo, Filspari, Fabhalta, Vanrafia, RAAS inhibitors, SGLT-2 inhibitors, sibeprenlimab, zigakibart, atacicept, povetacicept, ravulizumab, sefaxersen.
